that makes more sense but that is why we need the NNTT data from the final read out and the full sub-group analysis to evaluate it. If NNTT is 1000 you may be right. If it’s 10 you may be wrong. If it’s low enough and there are no side effects it may be worth treating people at risk of deterioration regardless. IMO.
MSB Trading 2021 - paradigm shift, page-108
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.030(2.73%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.05 | $28.73M | 25.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14264 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24626 | 3 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
-0.030 ( 2.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.05 | 5190842 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |